Articles with public access mandates - Joud Hajjar MD, PhD, MSLearn more
Not available anywhere: 3
Prophylactic antibiotics versus immunoglobulin replacement in specific antibody deficiency
J Hajjar, AL Nguyen, G Constantine, C Kutac, MN Syed, JS Orange, ...
Journal of Clinical Immunology 40, 158-164, 2020
Mandates: US National Institutes of Health
PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants
K Baysac, G Sun, H Nakano, EG Schmitz, AC Cruz, C Fisher, AC Bailey, ...
Journal of Allergy and Clinical Immunology 153 (1), 230-242, 2024
Mandates: European Commission
Risk factors of pneumonia in primary antibody deficiency patients receiving immunoglobulin therapy: data from the US immunodeficiency network (USIDNET)
MN Syed, C Kutac, JM Miller, R Marsh, KE Sullivan, ...
Journal of Clinical Immunology 42 (7), 1545-1552, 2022
Mandates: US Department of Veterans Affairs
Available somewhere: 21
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
T Fujii, RR Colen, MA Bilen, KR Hess, J Hajjar, ME Suarez-Almazor, ...
Investigational new drugs 36, 638-646, 2018
Mandates: US National Institutes of Health
Phase 2 study of pembrolizumab in patients with advanced rare cancers
A Naing, F Meric-Bernstam, B Stephen, DD Karp, J Hajjar, JR Ahnert, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
RR Colen, T Fujii, MA Bilen, A Kotrotsou, S Abrol, KR Hess, J Hajjar, ...
Investigational new drugs 36, 601-607, 2018
Mandates: US National Institutes of Health
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
I Petrache, J Hajjar, M Campos
Biologics: targets & therapy 3, 193, 2009
Mandates: US National Institutes of Health
T-cell agonists in cancer immunotherapy
Y Choi, Y Shi, CL Haymaker, A Naing, G Ciliberto, J Hajjar
Journal for immunotherapy of cancer 8 (2), 2020
Mandates: US National Institutes of Health
Use of genetic testing for primary immunodeficiency patients
JR Heimall, D Hagin, J Hajjar, SE Henrickson, HS Hernandez-Trujillo, ...
Journal of clinical immunology 38, 320-329, 2018
Mandates: US National Institutes of Health
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
RR Colen, C Rolfo, M Ak, M Ayoub, S Ahmed, N Elshafeey, P Mamindla, ...
Journal for immunotherapy of cancer 9 (4), 2021
Mandates: US National Institutes of Health
Constrained chromatin accessibility in PU. 1-mutated agammaglobulinemia patients
C Le Coz, DN Nguyen, C Su, BE Nolan, AV Albrecht, S Xhani, D Sun, ...
Journal of Experimental Medicine 218 (7), e20201750, 2021
Mandates: US National Science Foundation, US National Institutes of Health, Damon …
Increased incidence of fatigue in patients with primary immunodeficiency disorders: prevalence and associations within the US immunodeficiency network registry
J Hajjar, D Guffey, CG Minard, JS Orange
Journal of clinical immunology 37, 153-165, 2017
Mandates: US National Institutes of Health
Associations between the gut microbiome and fatigue in cancer patients
J Hajjar, T Mendoza, L Zhang, S Fu, SA Piha-Paul, DS Hong, F Janku, ...
Scientific Reports 11 (1), 5847, 2021
Mandates: US National Institutes of Health
Rubella virus infected macrophages and neutrophils define patterns of granulomatous inflammation in inborn and acquired errors of immunity
L Perelygina, R Faisthalab, E Abernathy, M Chen, LJ Hao, L Bercovitch, ...
Frontiers in immunology 12, 796065, 2021
Mandates: US National Institutes of Health, Federal Ministry of Education and Research …
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience
M Bupathi, J Hajjar, S Bean, S Fu, D Hong, D Karp, B Stephen, K Hess, ...
Investigational new drugs 35 (1), 59-67, 2017
Mandates: US National Institutes of Health
Are cancer patients at higher risk of death with COVID-19?
JJ Adashek, J Hajjar, RF Chemaly, R Kurzrock
Journal of immunotherapy and precision oncology 3 (2), 49-51, 2020
Mandates: US National Institutes of Health
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
C Tapia, PP Aung, S Roy-Chowdhuri, M Xu, F Ouyang, A Alshawa, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
B Stephen, J Hajjar, S Sarda, DY Duose, JM Conroy, C Morrison, ...
Journal for immunotherapy of cancer 11 (8), 2023
Mandates: US National Institutes of Health
Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens
M Xu, C Tapia, J Hajjar, S Sabir, R Colen, P Nagarajan, PP Aung, J Gong, ...
Journal of Immunotherapy and Precision Oncology 4 (2), 45-52, 2021
Mandates: US National Institutes of Health
Pediatric eosinophilia: a review and multiyear investigation into etiologies
TE Ness, TA Erickson, V Diaz, AB Grimes, R Rochat, S Anvari, J Hajjar, ...
The Journal of Pediatrics 253, 232-237. e1, 2023
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program